In a report released today, Jason Mills from Canaccord Genuity maintained a Buy rating on Boston Scientific Corp (BSX – Research Report), with a price target of $43. The company’s shares opened today at $35.80.
According to TipRanks.com, Mills is a top 100 analyst with an average return of 23.9% and a 70.0% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Shockwave Medical Inc.
Currently, the analyst consensus on Boston Scientific Corp is a Strong Buy with an average price target of $44.53, representing a 24.4% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $43 price target.
Boston Scientific Corp’s market cap is currently $50.08B and has a P/E ratio of 30.39. The company has a Price to Book ratio of 5.74.
Based on the recent corporate insider activity of 160 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.